Auvi Labs

Cover Block

Item	Detail
Company Name	Auvi Labs
Tagline	Wearable ultrasound designed to detect vascular access failure for hemodialysis patients. [Auvi Labs]
Headquarters	Champaign, IL
Founded	2024 [PitchBook]
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+) [Prospeo]
Funding Label	Pre-seed
Total Disclosed	~$136,000 (estimated) [Illinois Medicine, 2024][SignalBase]

Links

• Website: https://www.auvilabs.com/
• LinkedIn: https://www.linkedin.com/company/auvilabs
• YouTube: https://www.youtube.com/watch?v=fDuFXmx-7DY

Summary and Signal

Auvi Labs is developing a wearable ultrasound patch to detect vascular access failure in hemodialysis patients, a clinically significant problem that currently lacks a continuous, non-invasive monitoring solution [Auvi Labs]. The company, spun out of the University of Illinois at Urbana-Champaign in 2024, aims to reduce the high rate of complications and hospitalizations associated with arteriovenous fistula (AVF) stenosis by enabling early intervention [Illinois Medicine, 2024]. Its product, Beacon, is designed as a patch-like sensor patients would use for ten minutes daily to collect auditory data and flag narrowing before a complete failure occurs [YouTube]. The founding team leverages university research roots [Delta: HealthTech Innovators]. To date, the company has secured modest pre-seed capital, including a $35,000 award from the Cozad New Venture Challenge and a reported $101,000 seed round [Illinois Medicine, 2024] [SignalBase]. Over the next 12-18 months, key milestones will include advancing the hardware prototype, initiating clinical validation studies, and securing additional funding to navigate the FDA clearance process for a Class II medical device. Data Accuracy: YELLOW -- Core product claims are from primary sources, but funding details rely on a single unverified report and team backgrounds lack independent corroboration.

Company Overview

Auvi Labs is a 2024 company, spun out of the University of Illinois at Urbana-Champaign to address a specific and costly problem in kidney care [Auvi Labs]. The founding story centers on the high failure rate of vascular access points for hemodialysis patients [Illinois Medicine, 2024]. The company is headquartered in Champaign, Illinois [Crunchbase].

Key early milestones are anchored in the university's entrepreneurial ecosystem. The company secured second place and a $35,000 investment in the 2024 Cozad New Venture Challenge [Illinois Medicine, 2024]. This was followed by a reported $101,000 seed funding round [SignalBase].

Beyond these initial funding events, public milestones are sparse. The company's LinkedIn presence and a founder interview video indicate ongoing product development for a device named "Beacon" [YouTube] [LinkedIn, 2026]. The legal entity is listed as Auvi Labs Inc. in business directories [BBB]. Data Accuracy: YELLOW -- Core details (founding year, university spin-out, Cozad award) are confirmed by a primary university source. Other funding and entity details rely on single, unverified third-party reports.

The Product and the Stack

Auvi Labs is developing a hardware-software system aimed at the early detection of vascular access failure in hemodialysis patients. The company’s core product, named Beacon, is a non-invasive, patch-like wearable ultrasound sensor [Auvi Labs]. The device monitors arteriovenous fistulas (AVFs), collecting auditory information to detect narrowing [Illinois Medicine, 2024]. Patients wear the patch for approximately ten minutes daily, providing a routine check that could alert clinicians to intervene before a complete failure occurs [YouTube].

The technology stack combines custom ultrasound transducer hardware, signal processing algorithms, and a companion software platform. The public positioning emphasizes early detection and continuous monitoring for home use. Data Accuracy: YELLOW -- Product claims are consistent across the company's website and a university press release, but technical specifications and development status are not detailed.

The Market They Are Entering

The need for reliable, early-stage monitoring in chronic kidney disease is driven by a costly and growing patient population, where failure of vascular access is the primary cause of hospitalization. In the United States, over 800,000 people live with end-stage renal disease (ESRD), with approximately 560,000 receiving maintenance hemodialysis [National Institute of Diabetes and Digestive and Kidney Diseases]. Each relies on a functioning vascular access point, typically an arteriovenous fistula (AVF), which has a high failure rate.

Fistula stenosis is a leading cause of access failure, often requiring emergency surgical intervention. Current monitoring standards are intermittent and reactive. The clinical tailwind is a growing emphasis on value-based care models in nephrology. A wearable device that enables continuous, at-home monitoring aligns with this shift. Auvi Labs' proposition sits at the convergence of the remote patient monitoring (RPM) sector and the point-of-care ultrasound (POCUS) device market. Data Accuracy: YELLOW -- Market sizing is inferred from analogous public health data and adjacent sector reports; specific TAM for the product category is not cited.

The Competitive Field

Auvi Labs enters a medical device niche where competitive pressure is defined by varied approaches to solving the same underlying clinical problem. No direct, named competitor building an identical wearable ultrasound patch was identified in the public record.

• Incumbent procedural tools. Standard of care relies on periodic, in-clinic assessments using handheld Doppler ultrasound machines from companies like GE HealthCare and Philips.
• Emerging monitoring technologies. Companies like Flosonics Medical (wearable Doppler) and Bloom Technologies demonstrate the technical feasibility of wearable ultrasound, but their clinical applications differ.
• Adjacent substitutes. Includes superior surgical techniques, drug-coated balloons, or alternative renal replacement therapies.

Auvi Labs' edge is its specific focus on AVF narrowing. However, it lacks the established sales channels and reimbursement expertise of large medtech incumbents. A competitor like Butterfly Network could theoretically develop a fistula-monitoring accessory or software update. The most plausible 18-month competitive scenario hinges on clinical validation and partnership formation with a dialysis provider (like DaVita or Fresenius Medical Care).

Opportunity

The headline opportunity is to become the standard-of-care monitoring tool for the roughly 400,000 hemodialysis patients in the United States who rely on arteriovenous fistulas (AVFs) [Illinois Medicine, 2024]. The company's Beacon device aims to shift the paradigm from intermittent, clinic-based ultrasounds to continuous, patient-administered monitoring.

Scenario	What happens	Catalyst	Why it's plausible
Integrated Provider Partnership	Beacon becomes the preferred monitoring tool for a major dialysis provider.	A successful pilot study demonstrating Beacon's ability to reduce hospitalizations.	Dialysis providers are highly concentrated and have strong incentives to reduce costly complications [Crunchbase].
Data-Driven Predictive Platform	Auvi Labs evolves into a predictive analytics platform.	Accumulation of a proprietary longitudinal dataset.	The core product generates unique, time-series physiological data [Auvi Labs].
Indication Expansion	Technology is adapted to monitor other vascular conditions.	FDA clearance for the initial dialysis indication.	The sensor's fundamental function is applicable to multiple vascular pathologies.

Data Accuracy: YELLOW -- Core opportunity premise is well-sourced from company and clinical literature; growth scenarios are logical extrapolations from the product's stated function but lack specific, corroborated commercial milestones.

Sources

1. [Auvi Labs] Auvi Labs, Wearable Ultrasound for Vascular Access Monitoring | https://www.auvilabs.com/
2. [Illinois Medicine, 2024] Solution to Improve Dialysis Patient Care Earns CI MED Start-up Winning Investment | https://medicine.illinois.edu/news/solution-to-improve-dialysis-patient-care-earns-ci-med-start-up-winning-investment
3. [YouTube] How Auvi Labs is Building a Wearable Ultrasound Device | https://www.youtube.com/watch?v=fDuFXmx-7DY
4. [SignalBase] Auvi Labs Raises $101K Seed Funding to Advance Dialysis Access Monitoring | https://www.trysignalbase.com/news/funding/auvi-labs-raises-101k-seed-funding-to-advance-dialysis-access-monitoring
5. [PitchBook] Auvi Labs 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/688646-26
6. [Crunchbase] Auvi Labs - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/auvi-labs
7. [Prospeo] Prospeo company listing for Auvi Labs | https://prospeo.io/c/auvi-labs-email-format
8. [Delta: HealthTech Innovators] Delta: HealthTech Innovators - Podcast | https://podcasts.apple.com/ca/podcast/delta-healthtech-innovators/id1703827145
9. [LinkedIn, 2026] Paul Magelli - Greater Chicago Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/paulmagelli/
10. [BBB] BBB profile for Auvi Labs | https://www.bbb.org/us/il/chicago/profile/dialysis-clinic/auvi-labs-0654-1000139723